gener
bcpivebovgp
first
gener
ebov
vaccin
use
fulllength
ebov
gp
gene
note
depend
properti
ectop
express
envelop
protein
abil
prolifer
nonpropag
recombin
vector
regain
absenc
cognat
envelop
protein
happen
ebovgp
howev
doubl
mutat
gp
gene
complet
abrog
gpmediat
prolifer
recombin
bcpiv
vitro
fig
retain
antigen
addit
mutat
within
region
introduc
prevent
rna
edit
without
affect
amino
acid
sequenc
fig
b
result
vaccin
bcpivebovgp
incorpor
larg
amount
gp
protein
viral
particl
shown
western
blot
analysi
fig
consist
previou
report
transmembran
cytoplasm
region
envelop
protein
cognat
viru
necessarili
requir
effici
incorpor
exogen
protein
onto
virion
compar
authent
form
exogen
protein
fig
band
around
kda
weaker
authent
ebovgp
hybrid
form
extracellular
domain
ebovgp
transmembran
domain
cytoplasm
tail
f
upper
smear
band
much
stronger
authent
form
hybrid
form
differ
may
deriv
differ
level
glycosyl
incorpor
ebov
gp
wwwnaturecomscientificreport
wwwnaturecomscientificreport
visual
ectop
express
antigen
vector
particl
immunoelectron
microscopi
use
antiebovgp
neutral
monoclon
antibodi
recogn
conform
epitop
trimer
prefus
form
show
nativ
form
gp
protein
abundantli
present
viral
surfac
fig
colloid
gold
correspond
molecul
heterodim
gp
protein
coil
ribonucleocapsid
complex
clearli
visibl
insid
virion
induct
neutral
antibodi
ebov
abil
ebov
vaccin
induc
effici
humor
immun
igg
igg
mice
reveal
enzymelink
immunosorb
assay
measur
specif
antibodi
titer
sera
dilut
data
shown
pseudotyp
virusbas
inhibit
assay
measur
neutral
antibodi
titer
sera
fig
b
titer
compar
induc
ebola
vlp
mice
chimer
bear
ebov
gp
guinea
pig
antibodi
elicit
bcpivebovgp
also
induc
antibodydepend
enhanc
ade
pseudotyp
ebov
infect
fig
ade
activ
induc
bcpivebov
gp
also
compar
induc
ebola
vlp
mice
sera
monkey
surviv
challeng
ebov
suffici
neutral
activ
sera
indic
ade
effect
overcom
inhibitori
effect
sera
viru
infect
replicationcompet
vesicular
stomat
viru
vsv
ebovgp
previous
report
protect
lethal
ebov
challeng
nonhuman
primat
therebi
celldeplet
anim
succumb
ebov
infect
due
lack
induct
specif
antibodi
celldeplet
one
surviv
find
suggest
antibodi
play
import
role
vsvebovgpmedi
protect
ebov
challeng
although
bcpivebovgp
would
propag
vivo
contrast
vsvebovgp
toxic
protect
studi
primat
still
requir
futur
wwwnaturecomscientificreport
wwwnaturecomscientificreport
gener
bcpiv
carri
antigen
peptid
also
gener
vaccin
antigen
peptid
via
anoth
strategi
fig
made
three
type
recombin
vaccin
ectodomain
matrix
protein
peptid
influenza
viru
design
vaccin
peptid
slltevetpirnewgcrcndssdp
load
either
insid
outsid
side
viral
envelop
bcpiv
fuse
peptid
gene
cterminu
f
gene
hn
gene
construct
insid
version
peptid
gene
fuse
f
gene
stabli
transfect
vero
cell
packag
cell
produc
recombin
vector
outsid
version
peptid
gene
fuse
hn
gene
genom
use
produc
recombin
vector
vero
bcf
cell
genet
modifi
vero
cell
express
f
protein
sinc
f
hn
protein
opposit
orient
across
viral
membran
strategi
work
fig
peptid
detect
western
blot
analysi
case
fig
band
insid
peptid
abund
outsid
peptid
may
result
differ
express
peptid
insid
peptid
deriv
abund
stabl
express
packag
cell
outsid
peptid
deriv
transcript
vector
howev
possibl
better
incorpor
enhanc
stabil
insidepeptid
compar
outsid
peptid
exclud
insidetyp
peptidefus
protein
shown
local
within
viral
particl
immunoelectron
microscopi
fig
insid
type
would
suitabl
induc
cellular
immun
crosspresent
escap
neutral
antibodi
induct
lymphocyt
via
bcpiv
carri
antigen
peptid
melanoma
syngen
mous
tumor
model
cytotox
lymphocyt
ctl
induct
anoth
prerequisit
vaccin
vector
made
anticanc
vaccin
express
ctl
epitop
melanoma
use
strategi
shown
fig
test
effect
vaccin
inactiv
vaccin
mice
outsid
insid
peptid
load
bcpiv
envelop
suppress
melanoma
growth
tumorinfiltr
lymphocyt
fig
melanoma
ctl
epitop
kvprnqdwl
fuse
hn
peptid
locat
outsid
viral
membran
see
fig
ctl
epitop
rmfpnapyl
fuse
f
peptid
locat
insid
viral
membran
anticanc
drug
dacarbazin
intraperiton
inject
mgkg
time
vaccin
order
compar
effect
treat
bpl
inactiv
viral
genom
inject
bpl
treatment
confirm
suffici
abolish
express
transgen
bcpiv
data
shown
five
mice
per
group
use
mean
sd
shown
pbsinject
mice
euthan
day
c
hematoxylin
eosin
stain
transplant
tumor
left
pbsinject
group
day
middl
dacarbazineadminist
group
day
tumor
cell
diffus
die
right
vaccin
group
day
noteworthi
mice
permiss
transcript
replic
result
show
efficaci
vaccin
mice
present
studi
suggest
applic
potenti
vector
human
allow
much
effici
transcript
bcpiv
addit
use
inactiv
vaccin
without
transcript
platform
technolog
develop
base
nonpropag
ideal
properti
effici
deliveri
ectop
express
vaccin
antigen
achiev
high
yield
nonpropag
vector
essenti
establish
packag
cell
line
stabli
produc
delet
gene
product
use
verobcf
packag
cell
abl
obtain
maximum
titer
tcid
median
tissu
cultur
infecti
dose
ml
bcpivegfp
contrast
virosom
technolog
system
present
studi
requir
complex
process
antigen
incorpor
vector
system
util
selfassembl
viral
compon
vlp
revers
genet
allow
us
creat
stabl
steric
structur
antigen
addit
bcpiv
shown
intrins
adjuv
activ
capabl
deliv
gene
protein
intranas
transtrach
subcutan
intramuscular
administr
chimer
bear
ebov
gp
name
previous
report
howev
viru
replicationcompet
vsvebovgp
stabl
packag
cell
line
express
delet
gene
establish
similarli
attenu
express
ebov
gp
chimer
bovinehuman
vector
express
respiratori
syncyti
viru
f
protein
vaccin
human
anim
infecti
diseas
also
report
piv
vector
replicationcompet
although
replicationcompet
recombin
vaccin
benefici
massiv
induct
antigen
unless
advers
event
occur
replicationdefect
vaccin
safer
balanc
efficaci
likelihood
side
effect
vaccin
import
platform
technolog
may
use
fasttrack
vaccin
develop
address
variou
emerg
infecti
diseas
cancer
immunoelectron
microscopi
immunoelectron
microscopi
use
silverenhanc
techniqu
perform
describ
previous
brief
vectorproduc
verobcf
cell
cultur
chamber
fix
fresh
formaldehyd
glutaraldehyd
sodium
cacodyl
mm
cacl
ph
room
temperatur
rt
h
treat
phosphat
buffer
pb
ph
contain
block
ace
ds
pharma
biomed
suita
japan
proteas
inhibitor
cocktail
tablet
roch
diagnost
mannheim
germani
saponin
nacalai
usa
inc
san
diego
ca
usa
incub
rt
min
sampl
incub
antiebov
gp
absolut
antibodi
ltd
oxford
uk
mab
h
follow
reaction
antimous
igg
ab
coupl
nm
gold
particl
nanoprob
stoni
brook
ny
usa
rt
h
ab
dilut
pb
ph
contain
saponin
block
ace
proteas
inhibitor
cocktail
samplebound
gold
particl
silverenhanc
min
use
hqsilver
kit
nanoprob
sampl
wash
postfix
dehydr
embed
epoxi
resin
sampl
ultrathin
section
cut
stain
uranyl
acet
lead
citrat
observ
electron
microscop
jeol
tokyo
japan
zair
ebola
gppseudotyp
replicationincompet
vsv
contain
gfp
gene
instead
vsv
g
gener
describ
previous
pseudotyp
virus
suspend
growth
medium
mix
equal
volum
heatinactiv
mous
serum
dilut
medium
incub
min
rt
mixtur
inocul
confluent
vero
cell
grown
plate
infecti
unit
iu
well
twenti
hour
later
gfpposit
cell
count
viru
infect
quantifi
compar
gfpposit
cell
number
rel
percentag
infect
absenc
mous
serum
set
iu
replicationincompet
pseudotyp
vsv
determin
use
vero
cell
describ
previous
center
necrot
massiv
infiltr
lymphocyt
found
tumor
boundari
accumul
tlymphocyt
toward
tumor
cell
mice
vaccin
stain
blue
region
correspond
nuclei
id
c
cell
found
pbsinject
group
cell
scatter
dacarbazineadminist
group
howev
cell
accumul
tumor
boundari
vaccin
group
